Governance BioMarin Pharmaceutical Inc.

BMRN

US09061G1013

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:30:00 17/01/2026 am IST			5-day change	1st Jan Change
54.59 ^USD	-0.87%		-7.40%	-8.14%

14/01	BioMarin Pharmaceuticals Aims for Sustained Growth in 2026, Wedbush Says	MT
13/01	BioMarin Pharmaceutical Reports Preliminary 2025 Revenue, Details Asset Write-Down	MT

Executive Committee: BioMarin Pharmaceutical Inc.

Manager

Positions heldSince

Alexander Hardy

57 year

Chief Executive Officer	01/12/2023
President	01/12/2023

Gregory Friberg

52 year

Chief Tech/Sci/R&D Officer

30/09/2024

Brian Mueller

52 year

Comptroller/Controller/Auditor	02/09/2025
Director of Finance/CFO	29/01/2020

Kevin Eggan

Chief Tech/Sci/R&D Officer

05/10/2020

C. Guyer

64 year

Chief Tech/Sci/R&D Officer

01/05/2020

Amy Wireman

Human Resources Officer

01/01/2013

Stuart Bunting

Chief Tech/Sci/R&D Officer

Traci McCarty

Investor Relations Contact

George Davis

55 year

General Counsel	01/03/2004
Corporate Secretary	01/03/2004

Composition of the Board of Directors: BioMarin Pharmaceutical Inc.

Director

CommitteesSince

Randy Meier

66 year

Chairman	01/12/2023
Independent Dir/Board Member	13/09/2011

Ian Clark

64 year

Compensation Committee	01/01/2019
Governance Committee	08/07/2024
Nominating Committee	08/07/2024
Governance Committee Chair	01/08/2020
Nominating Committee Chair	01/08/2020
Audit Committee	01/08/2025

Elizabeth Anderson

68 year

Compensation Committee Chair
Governance Committee Chair
Nominating Committee Chair
Governance Committee	10/07/2019
Audit Committee	01/09/2022
Compensation Committee	01/09/2022

Timothy Walbert

59 year

Compensation Committee	01/06/2024
Governance Committee Chair	01/06/2023
Nominating Committee Chair	01/06/2023
Audit Committee	01/04/2024
Governance Committee	01/06/2024
Nominating Committee	01/06/2024

Athena Countouriotis

54 year

Compensation Committee	10/06/2019
Governance Committee	27/12/2023
Nominating Committee	27/12/2023
Audit Committee
Compensation Committee Chair	05/03/2020

Willard Dere

72 year

Compensation Committee	18/07/2016
Audit Committee	19/03/2018
Governance Committee Chair	19/03/2018
Nominating Committee Chair	19/03/2018

Barbara Bodem

58 year

Audit Committee	01/01/2024
Governance Committee	01/01/2024
Nominating Committee	01/01/2024
Finance Committee

May Kin Ho

73 year

Audit Committee	01/03/2018
Governance Committee	01/04/2021
Nominating Committee	01/04/2021

Mark Enyedy

62 year

Audit Committee	27/12/2023
Governance Committee	20/05/2025
Nominating Committee	20/05/2025

Robert Hombach

60 year

Compensation Committee	20/03/2022
Audit Committee Chair	11/03/2025

Alexander Hardy

57 year

Director/Board Member

01/12/2023

Latest Appointments: BioMarin Pharmaceutical Inc.

13/01	BioMarin Pharmaceutical Names Arpit Dave Chief Digital and Information Officer	MT
13/01	BioMarin Pharmaceutical Inc. Appoints Arpit Davé as Executive Vice President and Chief Digital and Information Officer	CI
18/12	BioMarin Pharmaceutical Inc. Appoints Rashmi Ramchandani as Chief Accounting Officer, Effective January 19, 2026	CI
11/11	Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth	CI
14/25/14	GeneDx Holdings Corp. Appoints Dr. Mimi Lee as Chief Precision Medicine Officer	CI
12/25/12	BioMarin Pharmaceutical Inc. Announces Resignation of Chief Accounting Officer ,Effective September 2, 2025	CI
01/25/01	Biomarin Pharmaceutical announces appointment of Ian T. Clark to board of directors	RE

More news

Former Officers and Directors: BioMarin Pharmaceutical Inc.

Insider

Positions held

SinceUntil

David Pyott

Director/Board Member	04/01/2016	20/05/2025
Independent Dir/Board Member	04/01/2016	20/05/2025

Elaine Heron

Director/Board Member	01/07/2002	20/05/2025
Independent Dir/Board Member	13/09/2011	20/05/2025

V. Lawlis

Director/Board Member	01/06/2007	21/05/2024
Independent Dir/Board Member	13/09/2011	21/05/2024

Jean-Jacques Bienaimé

Director/Board Member	30/11/2023	21/05/2024
Chief Executive Officer	16/05/2005	30/11/2023
Chairman	01/06/2015	30/11/2023
President	-	30/11/2023

Dennis Joseph Slamon

Director/Board Member	21/03/2014	21/05/2024
Independent Dir/Board Member	21/03/2014	21/05/2024

Jeff Ajer

Corporate Officer/Principal	01/09/2005	20/05/2024
Sales & Marketing	01/09/2005	-
Corporate Officer/Principal	01/08/2005	-

Philip Lo Scalzo

Compliance Officer	22/11/2012	01/01/2024
General Counsel	16/12/2010	22/11/2012

Debra Charlesworth

Public Communications Contact

01/01/2023

Michael Grey

Director/Board Member	15/12/2005	25/05/2021
Independent Dir/Board Member	13/09/2011	25/05/2021

Alan J. Lewis

Director/Board Member	01/06/2005	27/05/2020
Independent Dir/Board Member	13/09/2011	27/05/2020

Robert Baffi

Corporate Officer/Principal

01/05/2000

04/05/2020

Dan Spiegelman

Director of Finance/CFO

30/05/2012

29/01/2020

Richard Ranieri

Human Resources Officer

04/09/2013

01/01/2019

Barrie J. Carter

Corporate Officer/Principal

01/02/2013

01/12/2018

Kathryn Falberg

Director/Board Member

18/07/2016

01/06/2017

Ken Bate

Director/Board Member	01/09/2010	01/01/2017
Independent Dir/Board Member	01/09/2010	01/01/2017

Dan Oppenheimer

Corporate Officer/Principal

01/07/2002

01/06/2016

Vassiliki Economides

Corporate Officer/Principal

01/03/2015

01/06/2016

Pierre LaPalme

Director/Board Member	01/01/2015	01/06/2016
Chairman	01/08/2004	01/06/2015
Independent Dir/Board Member	01/08/2004	10/05/2012

Leonard Post

Chief Tech/Sci/R&D Officer

01/01/2010

01/06/2016

David J. Ellam

Corporate Officer/Principal

01/01/2010

01/01/2016

Joshua Grass

Public Communications Contact	01/01/2002	11/05/2009
Corporate Officer/Principal	11/05/2009	01/01/2016

William Young

Director/Board Member	22/09/2010	12/11/2015
Independent Dir/Board Member	22/09/2010	12/11/2015

Edward Conner

Chief Tech/Sci/R&D Officer

01/10/2013

01/11/2014

Suyash Prasad

Corporate Officer/Principal

01/12/2010

01/02/2014

Mark Wood

Human Resources Officer	01/05/2004	01/06/2013
Public Communications Contact	13/09/2011	01/06/2013

Stephen Aselage

Corporate Officer/Principal

01/07/2005

01/09/2012

Jeffrey Cooper

Director of Finance/CFO

01/10/2003

01/05/2012

Jackie Walling

Chief Tech/Sci/R&D Officer

25/05/2010

01/03/2012

Joseph Klein

Director/Board Member

01/06/2005

19/03/2010

Alejandro Dorenbaum

Chief Tech/Sci/R&D Officer

01/01/2009

Henry Fuchs

Chief Tech/Sci/R&D Officer

01/03/2009

Emil Kakkis

Chief Tech/Sci/R&D Officer

01/09/1998

27/02/2009

S. Michael Imperiale

Corporate Officer/Principal

01/01/2009

Eduardo Von Pervieux

Chief Tech/Sci/R&D Officer

25/05/2010

Gordon Vehar

Chief Tech/Sci/R&D Officer

28/01/2008

Bill Aliski

Corporate Officer/Principal

01/12/2005

01/01/2008

Lewis Chapman

Sales & Marketing

01/07/2007

Erich Sager

Director/Board Member

01/11/1997

01/03/2006

John Ditton

Sales & Marketing

01/01/2006

Christopher Starr

Chief Tech/Sci/R&D Officer	-	01/01/2006
Founder	01/01/1997	01/01/2006

Louis Drapeau

Chief Executive Officer	01/01/2004	01/06/2005
Director of Finance/CFO	01/01/2004	23/08/2005

Kim Tsuchimoto

Comptroller/Controller/Auditor	01/02/1997	01/06/2005
Treasurer	01/02/1997	01/06/2005

Vimal Srivastava

Corporate Officer/Principal

01/01/2005

John Urquhart

Director/Board Member

01/07/2003

01/01/2005

Todd C. Zankel

Chief Tech/Sci/R&D Officer

01/01/1997

01/01/2005

David Scott Geyer

Corporate Officer/Principal

01/02/2004

Matt Patterson

Corporate Officer/Principal

01/01/1998

01/01/2004

Robert A. Heft

Corporate Officer/Principal

01/01/2001

01/01/2004

Fredric D. Price

Chief Executive Officer	01/01/2000	01/01/2004
Chairman	01/01/2000	01/01/2004

Vijay Samant

Director/Board Member

01/01/2002

01/01/2004

Franz L. Cristiani

Director/Board Member

01/07/2002

Raymond Anderson

Chief Operating Officer	01/06/1998	01/01/2002
Director of Finance/CFO	01/06/1998	01/01/2001

Ansbert Gadicke

Director/Board Member

01/01/1997

01/01/2001

Amy Lea Waterhouse

General Counsel

01/01/2000

Steven Jungles

Corporate Officer/Principal

01/06/1999

Stuart J. Swiedler

Chief Tech/Sci/R&D Officer

01/06/1998

Grant W. Denison

Director/Board Member	21/03/1997	-
Chief Executive Officer	21/03/1997	01/01/2000
Founder	21/03/1997	-

Andria Langenberg

Chief Operating Officer	-	-
Chief Tech/Sci/R&D Officer	-	-

Jeffrey Landau

Chief Administrative Officer

Barbara Wuebbels

Corporate Officer/Principal

Monica Miller

Corporate Officer/Principal

Steve Glass

Corporate Officer/Principal

Leonid Katz

Corporate Officer/Principal

Charles Olson

Corporate Officer/Principal

Zhong Qi Shao

Corporate Officer/Principal

Kevin Scott

Corporate Officer/Principal

Gwynn Williams

Director/Board Member

Lisa M. Bell

General Counsel

Mary Newman

General Counsel

Valerie Smith

Corporate Officer/Principal

Bob Purcell

Public Communications Contact

13/09/2011

Philip A. Pemberton

Corporate Officer/Principal

Reinhard Gabathuler

Chief Tech/Sci/R&D Officer

Dawn Blessing

Corporate Officer/Principal

John Edward Ilett

Director/Board Member	-	-
General Counsel	-	-

Age distribution of managers

Parity Men Women

Male	18
Female	6

Of which Executive Committee

Male	7
Female	2

Of which Directors

Male	9
Female	2

Revisions

Révisions CA 1 an

Révisions CA 4 mois

Révisions CA 1 mois

Révisions BNA 1 an

Révisions BNA 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.

Employees

3,040

Sector

Pharmaceuticals

Calendar

25/02 - Q4 2025 Earnings Release (Projected)

More about the company